With another quality scandal on its hands with diabetes drug metformin, the FDA could be looking at another global recall of a commonly used med. With COVID-19 challenging the FDA’s ability to keep up with inspections––and potentially putting dangerous drugs in U.S. patients’ hands––is metformin just the beginning?
The COVID-19 pandemic has exposed significant flaws in the FDA’s ability to adequately inspect drugs produced by foreign manufacturers and might cause quality concerns in the U.S. supply for years to come, Valisure CEO David Light testified Tuesday during a Senate Finance Committee hearing.
With COVID-19 freezing FDA inspections of foreign plants since March, Light warned senators that the combination of a strained global supply chain and structural issues in the FDA’s testing of foreign drugs could damage consumer confidence.
Sponsored by Lubrizol Life Science
[Webinar] Cannabinoid Formulation – from Farm to Pharma
Wednesday, June 24, 2020 | 12pm ET / 9am PT
A handful of cannabinoid-based pharmaceutical products are on the market today, and an ever-growing number are in the global development pipeline. This webinar will explore key considerations in developing cannabinoid-based pharmaceutical products, including an overview of global pharmaceutical cannabinoid usage today, common challenges formulating with CBD and other cannabinoids, and more.
“Manufacturing problems that arise from the escalated production of drugs [tied to COVID-19] and a lack of FDA inspectors on the ground at foreign plants could produce a domino effect for years to come,” Light said. “The lifecycle of a drug in the supply chain is many years, and it could be many more before significant and serious issues are found, let alone addressed.”
Light’s testimony comes just days after the FDA asked five metformin manufacturers to pull their extended-release metformin products. The agency had found high levels of N-Nitrosodimethylamine (NDMA), a likely human carcinogen, in tested lots.
Valisure, an independent testing laboratory, helped drive those voluntary recalls after discovering contaminated lots of metformin in March, calling the FDA’s prior findings into question.
The FDA said it was working with drugmakers to determine whether the recommended recalls would cause a shortage in the U.S. The move doesn’t apply to metformin’s immediate-release formulation, and the FDA specified that “there are additional manufacturers of the metformin ER formulation that supply a significant portion of the U.S. market, and their products are not being recalled.”
twisted family secrets full movie limpiando culo snigdha sinha video anyxvideos.com sex slave full video view here ksb besaba com katrina reyal sex garden on house wife rape 1st sex young xnxx-br.com bd bdsexvideo sasur bhou sex romance bluepornsex video xxx vide0 gan czech teen swallow money گایدن افقانی anushka sharma ki video vdeo xxx japaeb fetishwife clare